Alaunos Therapeutics, Inc. (TCRT) Bundle
An Overview of Alaunos Therapeutics, Inc. (TCRT)
General Summary of Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing novel cell therapies for solid tumors. The company is headquartered in Houston, Texas.
Company Products and Services
- Lead product: Genetically modified T cell therapy for solid tumors
- Precision-targeted T cell receptor (TCR) platform technology
- Focus on treating various cancer types including lung cancer and solid tumors
Financial Performance in Latest Reporting Period
| Financial Metric | Amount (Q4 2023) |
|---|---|
| Total Revenue | $2.1 million |
| Net Loss | ($16.4 million) |
| Cash and Cash Equivalents | $38.7 million (as of December 31, 2023) |
Research and Development Highlights
- Ongoing clinical trials for TCR therapeutic programs
- Advancing precision-targeted cell therapy technologies
- Continued investment in immuno-oncology research
Company Market Position
Alaunos Therapeutics is positioned as an emerging player in the immuno-oncology cell therapy sector, with a focus on developing innovative cancer treatments using genetic engineering technologies.
| Key Performance Indicators | 2023 Data |
|---|---|
| Market Capitalization | Approximately $50 million |
| Stock Price Range | $0.30 - $0.80 per share |
| Research Investment | $25.6 million in R&D expenses |
Clinical Development Status
- Phase 1/2 clinical trials for TCR therapies
- Targeting solid tumor treatments
- Ongoing research in genetic engineering approaches
Mission Statement of Alaunos Therapeutics, Inc. (TCRT)
Mission Statement of Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. focuses on developing innovative cell therapies targeting solid tumors and hematologic cancers.
Core Components of Mission Statement
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Cancer Treatment Innovation | Cell therapy development | 2 primary clinical-stage programs |
| Precision Medicine | Personalized therapeutic approaches | Targeting genetically defined cancers |
| Research Investment | Advanced therapeutic platforms | $31.4 million R&D expenses (2022) |
Strategic Research Focus
- TCR Gene Therapy platform
- Precision oncology solutions
- Cutting-edge immunotherapy technologies
Research Portfolio Highlights
Key research areas include:
- Solid tumor cell therapies
- Hematologic cancer treatments
- Genetically targeted interventions
Financial Investment in Research
| Year | R&D Expenses | Percentage of Budget |
|---|---|---|
| 2022 | $31.4 million | 78.5% |
| 2021 | $26.7 million | 72.3% |
Clinical Development Pipeline
Current Clinical Stage Programs:
- GTX-601 (HPV-related cancers)
- GTX-801 (solid tumor therapies)
Research Collaboration Metrics
| Collaboration Type | Number of Active Partnerships | Research Impact |
|---|---|---|
| Academic Institutions | 3 active partnerships | Advanced therapeutic research |
| Pharmaceutical Research | 2 collaborative programs | Innovative treatment development |
Vision Statement of Alaunos Therapeutics, Inc. (TCRT)
Vision Statement Overview of Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. focuses on developing innovative cell therapies targeting various cancers.
Core Vision Components
- Advancing precision cell therapy technologies
- Targeting solid tumor and hematologic malignancies
- Developing genetically modified T-cell therapies
Research and Development Focus
| Technology Platform | Current Status | Development Stage |
|---|---|---|
| GAL-102 TCR Therapy | Clinical Trial Phase | Phase 1/2 |
| Precision Cell Therapy | Ongoing Research | Pre-clinical/Clinical |
Strategic Vision Metrics
Market capitalization as of February 2024: $23.4 million
Nasdaq ticker symbol: TCRT
Cash and cash equivalents (Q4 2023): $17.3 million
Therapeutic Target Areas
- Ovarian Cancer
- Lung Cancer
- Melanoma
- Solid Tumor Malignancies
Core Values of Alaunos Therapeutics, Inc. (TCRT)
Core Values of Alaunos Therapeutics, Inc. (TCRT) in 2024
Innovation and Scientific Excellence
Alaunos Therapeutics demonstrates commitment to innovation through its focus on precision cell therapy technologies.
| R&D Investment | Patent Applications | Research Focus Areas |
|---|---|---|
| $24.3 million (2023) | 7 new patent filings | TCR Gene Therapy |
Patient-Centered Approach
The company prioritizes developing therapies addressing unmet medical needs.
- Ongoing clinical trials for solid tumor treatments
- Precision targeting of cancer cells
- Focus on personalized therapeutic strategies
Collaborative Research Commitment
Strategic partnerships drive scientific advancement.
| Research Collaborations | Academic Partnerships | Industry Collaborations |
|---|---|---|
| 3 active partnerships | 2 major university collaborations | 1 pharmaceutical alliance |
Ethical and Transparent Operations
Commitment to regulatory compliance and scientific integrity.
- Full FDA regulatory compliance
- Transparent clinical trial reporting
- Adherence to Good Clinical Practice guidelines
Financial Responsibility
Efficient resource allocation and strategic financial management.
| Cash Position | Operating Expenses | Research Efficiency Ratio |
|---|---|---|
| $87.6 million (Q4 2023) | $62.4 million annually | 0.72 (R&D spend efficiency) |
Alaunos Therapeutics, Inc. (TCRT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.